抑制补体C1s改善冷凝集素病中的重度溶血性贫血:一项首次人体试验
该首次人体1b期试验纳入10例冷凝集素病(CAD)患者,评估抗C1s抗体sutimlimab。患者先接受10 mg/kg试验剂量,1至4天后接受60 mg/kg全剂量,并每周追加3次60 mg/kg。所有输注耐受良好,无药物相关严重不良事件。10例中7例血红蛋白升高>2 g/dL;6周内血红蛋白中位升高3.9 g/dL(四分位距1.3-4.5 g/dL;95%CI 2.1-4.5;P=.005)。
要点
- sutimlimab在冷凝集素病中快速抑制补体C1s介导的溶血,10例中7例血红蛋白升高>2 g/dL。
- 6周内血红蛋白中位升高3.9 g/dL(95%CI 2.1-4.5;P=.005),6例既往输血患者均脱离输血。
- 停药后3至4周药物清除时溶血性贫血复发;再次暴露于sutimlimab可重现溶血控制。
核心结论
- sutimlimab安全、耐受良好,快速停止冷凝集素病患者的C1s补体介导溶血,显著升高血红蛋白并避免输血需求。
研究设计与样本
- 首次人体试验的1b期组分,纳入10例冷凝集素病患者;患者接受10 mg/kg sutimlimab试验剂量,1至4天后接受60 mg/kg全剂量,并每周追加3次60 mg/kg。
- 试验注册于www.clinicaltrials.gov,编号#NCT02502903。
主要发现
- 所有输注均耐受良好,无需预处理;未观察到药物相关严重不良事件。
- 10例冷凝集素病患者中7例应答,血红蛋白升高>2 g/dL。
- sutimlimab在第一周内使血红蛋白中位升高1.6 g/dL,6周内中位升高3.9 g/dL(四分位距1.3-4.5 g/dL;95%CI 2.1-4.5;P=.005)。
- sutimlimab快速消除血管外溶血,大多数患者胆红素水平在24小时内正常化,4例患者结合珠蛋白水平在1周内正常化。
- 末次sutimlimab给药后3至4周药物从循环清除时溶血性贫血复发;在指定患者项目中再次暴露于sutimlimab重现溶血性贫血的控制;全部6例既往输血患者治疗期间均脱离输血。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cold agglutinin disease is a difficult-to-treat autoimmune hemolytic anemia in which immunoglobulin M antibodies bind to erythrocytes and fix complement, resulting in predominantly extravascular hemolysis. This trial tested the hypothesis that the anti-C1s antibody sutimlimab would ameliorate hemolytic anemia. Ten patients with cold agglutinin disease participated in the phase 1b component of a first-in-human trial. Patients received a test dose of 10-mg/kg sutimlimab followed by a full dose of 60 mg/kg 1 to 4 days later and 3 additional weekly doses of 60 mg/kg. All infusions were well tolerated without premedication. No drug-related serious adverse events were observed. Seven of 10 patients with cold agglutinin disease responded with a hemoglobin increase >2 g/dL. Sutimlimab rapidly increased hemoglobin levels by a median of 1.6 g/dL within the first week, and by a median of 3.9 g/dL (interquartile range, 1.3-4.5 g/dL; 95% confidence interval, 2.1-4.5) within 6 weeks (P = .005). Sutimlimab rapidly abrogated extravascular hemolysis, normalizing bilirubin levels within 24 hours in most patients and normalizing haptoglobin levels in 4 patients within 1 week. Hemolytic anemia recurred when drug levels were cleared from the circulation 3 to 4 weeks after the last dose of sutimlimab. Reexposure to sutimlimab in a named patient program recapitulated the control of hemolytic anemia. All 6 previously transfused patients became transfusion-free during treatment. Sutimlimab was safe, well tolerated, and rapidly stopped C1s complement-mediated hemolysis in patients with cold agglutinin disease, significantly increasing hemoglobin levels and precluding the need for transfusions. This trial was registered at www.clinicaltrials.gov as #NCT02502903.
引用
- Jäger U, D'Sa S, Schörgenhofer C, et al. Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial. Blood. 2018. PMID: 30559259. doi:10.1182/blood-2018-06-856930
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。